Clinical Trial Update: CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study [Phase 4]

View source ↗

Summary

Phase 4 prospective study evaluating contrast-enhanced mammography to reduce unnecessary biopsies for less-than highly suspicious breast abnormalities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Margarita Louise Zuley | Conditions: Breast Cancer | Phase 4 | Status: RECRUITING